Table 5.

Transcription factors (TFs) revealed with upstream network analysis: LR12 + TAK242 treated vs. scrambled peptide and vehicle (30% ethanol)-treated arteries. DEGs with higher expression in LR12 + TAK242-treated group (log₂ < −2, p < 0.05) and with higher expression in scrambled peptide-treated group (log₂ > 2, p < 0.05).

Associated with Activated Networks	DEGs (log2 < −2, p < 0.05)	DEGs (log2 > 2, p < 0.05)	DEGs (log2 < 2 or >−2, p < 0.05)
STAT3	AGT, ALDH1A1, CAT, CEBPA, LDHB	ALAS2, ARG1, BCL3, SELP COL5A1, CXCL8, EGR1,EGR3, ICOS, IL1R1,IL2RB, MYC, SBNO2, NFATC2, PLAGL1, PRDM1	CXCR5, EGR2, IL9R
TP53	ALDH1A1, ALDH1A2, APOE, ALDH9A1, ASS1, BMX, CAT, CEBPA, DDIT4L, ECH1, LDHB, PPARG, RAMP2, SCD, TCAP, TMOD4	ADAM8, ARG1, BCL3, CXCL8, EGR1, EGR3, MYC, DMRT1, ECM1, EDIL3, ITGA2B, ITGB7, NCOR2, PDE4B, PRDM1, SELP, SERPINB2, VDR	EGR2
HTT	AGT, APOE, CEBPA, LDHB, MYL1, PPARG	ADAMTS4, BCL3, EGR1, PDE4B, COL6A3, PPRC1, PTPN22, RGS14	CXCR5, EGR2
ETS1	HPSE	CD27, CD69, CRTAM, EGR1, IL2RB, MYC, ITGA2B, PRDM1
BCL11B		CXCL8
RELA	AGT, APOE, PPARG	BCL3, CCL22, CCR7, CD69, CXCL8, EGR1, GP1BB, MYC, NFATC2, PDE4B, PRDM1, PTX3, SELP
VDR	AGT, MYH8, PNPLA2, PPARG	CXCL8, EGR1, MYC, ITGB7, STAT4, VDR
HDAC4	MYLK2, MYOT	SERPINB2	EGR2
RELB		CXCL8, MYC, PRDM1, STAT4
KDM5A	MYH4, MYH8, MYL1, TCAP TNNC2
ASXL1	PLIN1, PPARG, SCD
LEF1		ECM1, MYC, PRDM1
NFKB2		CCR7, CXCL8, MYC	CXCR5
NUPR1	MMD	ABL2, CXCL8, MYC
Associated with inhibited networks
GFI1	CEBPA,	BCL3, CCR7,CXCL8, IL1R1, ITGB7, MYC, STAT4, VDR	EGR2
PPARGC1A	AGT, APOD, CAT, LDHB, MYC, PLIN5, PNPLA2, SCD, SEMA3G	ADAMTS1, IL1R2, COL6A3, OSMR, STC1
MYOD1	AGT, ASS1, MYH4, MYL1, MYLPF, TNNC2
HLX	SEMA3G	CXCL8, EGR1, MYC, PRDM1,
SPDEF		COL5A1, COL6A3, CXCL8
RB1	CEBPA, MYH4, MYH8, MYL1, PPARG, RAMP2, TCAP, TNNC2	COL5A1, CXCL8, EGR1, EGR3, MYC, OSMR, PTX3
IKZF2		CD69, ICOS, IL1R1, LAG3, STAT4
NCOA1	CEBPA, PPARG	EGR1, MYC
NKX2-3	CAVIN2	CXCL8, RNF213
NEUROG1	ASS1, CAVIN2
KMT2D	IGSF1, PPARG